Holen Sie sich die Stockscreener-App
6.57
7.00%
0.43
Vorhandelsmarkt:
6.67
0.10
+1.52%
Schlusskurs vom Vortag:
$6.14
Offen:
$6.25
24-Stunden-Volumen:
2.12M
Relative Volume:
1.44
Marktkapitalisierung:
$556.24M
Einnahmen:
$20.65M
Nettoeinkommen (Verlust:
$-192.65M
KGV:
-2.5367
EPS:
-2.59
Netto-Cashflow:
$-134.39M
1W Leistung:
+25.14%
1M Leistung:
+14.46%
6M Leistung:
-4.64%
1J Leistung:
-44.97%
1-Tages-Spanne:
$6.145
$6.90
1-Wochen-Bereich:
$5.315
$6.90
52-Wochen-Spanne:
$4.305
$19.34
Verve Therapeutics Inc Stock (VERV) Company Profile
Firmenname
Verve Therapeutics Inc
Sektor
Branche
Telefon
(978) 501-3026
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie VERV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
6.57 | 556.24M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-10-06 | Eingeleitet | Credit Suisse | Neutral |
| 2022-08-25 | Hochstufung | Stifel | Hold → Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-07-12 | Eingeleitet | Guggenheim | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-12 | Eingeleitet | Jefferies | Buy |
| 2021-07-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
Equities Analysts Offer Predictions for VERV FY2025 Earnings - MarketBeat
(VERV) Trading Advice - Stock Traders Daily
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading 8.6% HigherTime to Buy? - MarketBeat
GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Harbor Capital Advisors Inc. Sells 11,980 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Stake Raised by Barclays PLC - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC - Defense World
Analysts’ Revisions Show Improving Sentiment For Verve Therapeutics Inc (NASDAQ: VERV) - Stocks Register
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation - AccessWire
Verve Therapeutics Advances Heart Disease Gene Therapy Pipeline, Extends Cash Runway to 2027 - StockTitan
Learn to Evaluate (VERV) using the Charts - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation - AccessWire
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Verve Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2025-01-05 | Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Grants New Employee RSU Awards Under 2024 Inducement Plan - StockTitan
Verve Therapeutics (NASDAQ:VERV) Trading 6.2% HigherWhat's Next? - MarketBeat
Franklin Resources Inc. Buys 5,914 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect - AccessWire
Geode Capital Management LLC Raises Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
2025-01-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect | NDAQ:VERV | Press Release - Stockhouse Publishing
Barclays PLC Grows Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Barclays PLC Purchases 129,944 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Verve Therapeutics (NASDAQ:VERV) Trading Down 5.9%What's Next? - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Raised by Stifel Financial Corp - Defense World
State Street Corp Boosts Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
State Street Corp Has $20.59 Million Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation - AccessWire
(VERV) Technical Pivots with Risk Controls - Stock Traders Daily
Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - The Eastern Progress Online
Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - The Eastern Progress Online
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
2024-12-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation - AccessWire
Verve Therapeutics Slides As Insider Purchases Lose Another US$65k - Yahoo Finance
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - The Eastern Progress Online
Charles Schwab Investment Management Inc. Acquires 126,110 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out - AccessWire
2024-12-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out | NDAQ:VERV | Press Release - Stockhouse Publishing
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact The Gross Law Firm - Victoria Advocate
Finanzdaten der Verve Therapeutics Inc-Aktie (VERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):